STVN
NYSE · Life Sciences Tools & Services
Stevanato Group Spa
$21.70
+0.19 (+0.88%)
Financial Highlights (FY 2026)
Revenue
1.21B
Net Income
142.50M
Gross Margin
29.6%
Profit Margin
11.8%
Rev Growth
+6.4%
D/E Ratio
0.32
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 29.6% | 29.6% | 51.2% | 51.2% |
| Operating Margin | 16.8% | 15.1% | 14.1% | 13.0% |
| Profit Margin | 11.8% | 11.2% | 9.2% | 10.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.21B | 1.14B | 2.66B | 2.46B |
| Gross Profit | 357.83M | 336.18M | 1.36B | 1.26B |
| Operating Income | 202.61M | 171.32M | 376.02M | 319.21M |
| Net Income | 142.50M | 120.49M | 245.63M | 251.38M |
| Gross Margin | 29.6% | 29.6% | 51.2% | 51.2% |
| Operating Margin | 16.8% | 15.1% | 14.1% | 13.0% |
| Profit Margin | 11.8% | 11.2% | 9.2% | 10.2% |
| Rev Growth | +6.4% | +6.4% | +4.0% | +22.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 723.65M | 723.65M | 579.44M | 635.38M |
| Total Equity | 2.29B | 2.29B | 1.94B | 2.00B |
| D/E Ratio | 0.32 | 0.32 | 0.30 | 0.32 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 215.38M | 192.23M | 513.68M | 453.60M |
| Free Cash Flow | — | — | 349.36M | 309.93M |